-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 F3ZsQIIolCSfM5VtbA4Wgh6fr2H9D2OtYTgiziqLLPUj4flZNwPbEriKqyNPhvyk
 h8HJ3bUPyg43m5+vDONXPw==

<SEC-DOCUMENT>0000950123-10-073983.txt : 20100806
<SEC-HEADER>0000950123-10-073983.hdr.sgml : 20100806
<ACCEPTANCE-DATETIME>20100806115048
ACCESSION NUMBER:		0000950123-10-073983
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100806
DATE AS OF CHANGE:		20100806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		10997026

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c04441e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 OR 15(d) of The Securities Exchange Act of 1934</B>
</DIV>

<!-- xbrl,dc -->
<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): August 5, 2010</B></DIV>
<!-- /xbrl,dc -->
<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD nowrap align="center" valign="top"><B>Delaware
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>000-52091
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>87-0455038</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Commission File Number)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(IRS Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="48%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD align="center" valign="top"><B>1900 Lake Park Drive<BR>
Suite 380<br> Smyrna, Georgia
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="bottom"><B>&nbsp;<BR>30080</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(Address of principal executive offices)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(678) 384-7220</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B></B></DIV>

<DIV align="center" style="font-size: 10pt"><FONT style="border-top: 1px solid #000000">(Former name or former address, if changed since last report.)</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">







<DIV style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to
time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV  style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition</B>
</DIV>


<DIV style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On August&nbsp;5, 2010 we issued a press release reporting our results of operations for the
quarter ended June&nbsp;30, 2010. A copy of the press release is attached to this Current Report.
</DIV>

<DIV  style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>



<DIV style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">Exhibit&nbsp;99.1 Press Release
</DIV>

<DIV style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<DIV  style="font-size: 10pt; margin-top: 10pt">Dated: August&nbsp;6, 2010
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c04441exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><b>Exhibit&nbsp;99.1</b>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><IMG src="c04441c0444101.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
ANNOUNCES SIX MONTH 2010 FINANCIAL RESULTS<BR>
AND PROVIDES OPERATIONAL UPDATE</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>ATLANTA, Ga., August&nbsp;5, 2010 </B>&#151; GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based,
biopharmaceutical firm (the &#147;Company&#148;) developing vaccines that prevent and fight Human
Immunodeficiency Virus (HIV)&nbsp;infections, today announced its financial results and provided an
operational update for the six months ended June&nbsp;30, 2010.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Review of Financial Results</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax reported a net loss of $933,089 ($0.06 per share) for the three months ended June&nbsp;30, 2010,
compared to $1,348,654 ($0.09 per share) for the same period in 2009. For the six months ended June
30, 2010, the Company&#146;s net loss was $1,623,878 ($0.10 per share) as compared to $2,210,163 ($0.15
per share) in 2009.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Net losses were partially offset by revenues related to the Company&#146;s grant from the NIH in support
of the its HIV/AIDS vaccine development activities; such revenues were $1,737,169 and $3,075,729
for the three month and six month periods of 2010, respectively, as compared to $752,800 and
$1,462,955 for the three month and six month periods of 2009, respectively.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">As of June&nbsp;30, 2010, the Company reported cash balances totaling $1,807,647, as compared to
$3,515,784 at December&nbsp;31, 2009.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Summarized financial information is presented below. Further information concerning the Company&#146;s
financial position and results of operations is included in its Quarterly Report on Form 10-Q to be
filed with the Securities and Exchange Commission.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Operations / Clinical Update</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax President and Chief Executive Officer, Robert T. McNally, Ph.D. provided the following
updates:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><U>Phase 2a Preventative Vaccine Trial Progressing</U></DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Our preventative HIV vaccine candidate is progressing in a Phase 2a clinical trial being
conducted and funded by the HIV Vaccine Trials Network (HVTN). Based on current patient
enrollment rates, we expect the 300 participants in this trial to be fully enrolled by the
end of 2010 and completed during 2011. Our Phase 2a trial has been expanded from 225 to 300
participants to include an arm gathering additional data on three MVA injections, without
the use of the DNA component, which is an addition to the original arm testing two DNA
priming and two MVA boosting injections. Adding the simpler MVA-only arm to the trial was
supported by scientific and clinical data. The final decision on which inoculation format
to take forward into the next set of clinical trials will be made once sufficient clinical
data are available.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax, Inc.</B><BR>
<B>Add 1</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><U>Therapeutic Trial Screening Volunteers</U></DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">With regard to our therapeutic vaccine candidate, the AIDS Research Consortium of Atlanta
(ARCA)&nbsp;recently began patient recruitment for a Phase 1 clinical trial. We intentionally
designed this groundbreaking trial, which will be the first assessment of the vaccine
performance in
HIV infected humans, with stringent enrollment criteria for safety. The trial is primarily
designed as a safety study, but will also collect and report data on the vaccine&#146;s ability
to elicit protective immune responses and control re-emergent virus during a pause in drug
treatment. Thus far, 23 individuals have been screened for possible participation in the
trial. Out of these, 6 candidates remain for evaluation. As part of our protocol, a
volunteer must have begun drug treatment in the first year of infection and have achieved 6
months of stable viral control on drug treatment before entry into the trial and receipt of
the first vaccination. We expect this trial to begin generating vaccine safety and
performance data during the first half of 2011, with trial completion within 24 to 36
months.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><U>Phase 1 Preventative Trial Planning for our Adjuvanted Vaccine</U></DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Our pipeline product, which uses an adjuvant to boost the immune system response,
demonstrated impressive results in preclinical trials. In February this year, Dr.&nbsp;Harriet
Robinson, our Chief Scientific Officer, presented these data at the <I>Conference on
Retroviruses and Opportunistic Infections (CROI). </I>The study investigated the use of
co-expressed GM-CSF (granulocyte/macrophage colony-stimulating factor) as an adjuvant with
the DNA priming component for the GeoVax DNA/MVA vaccine. Results from this study showed
total protection from infection (no evidence of infection) from simian immunodeficiency
virus (SIV &#151; monkey version of HIV) in 70% of animals who were given 12&nbsp;weekly high-dose
rectal exposures to the SIV virus. We are very excited about the potential of this product
as a second generation preventative HIV vaccine, and are targeting the start of Phase 1
human clinical testing in mid to late 2011.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>About GeoVax Labs, Inc.</I></B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human
Immunodeficiency Virus &#151; that leads to AIDS) and other infectious agents. Our goals include
developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing these
vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety
and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative
Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA
and MVA vaccines, their ability to raise anti-HIV humoral (antibody)&nbsp;and cellular (cytotoxic T
cell) immune responses, as well as, the vaccines&#146; safety. Successful results from Phase 1 testing
supported the initiation of the first Phase 2 testing. GeoVax&#146;s Phase 2 human trial began in
January&nbsp;2009 and will ultimately involve 300 participants at sites in the United States and South
America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for
individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and
distribution rights in several global markets in return for upfront fees, collaborative development
agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and
distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>Forward-Looking Statements</I></B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Certain statements contained in this release, including those relating to postponement of the
offering, as well as statements containing words like &#147;plans,&#148; &#147;expects,&#148; and other similar
expressions in this press release or the Company&#146;s other public communications, are forward-looking
statements that involve a number of risks and uncertainties. All such forward-looking statements
are subject to certain risks and uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. These risks and uncertainties include, but are not
limited to whether: GeoVax can develop and manufacture its vaccines with the desired
characteristics in a timely and economic manner, GeoVax&#146;s vaccines will be safe for human use,
GeoVax&#146;s vaccines will effectively prevent AIDS in humans, GeoVax vaccines will receive regulatory
approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine
development, there is development of competitive products that may be more effective or easier to
use than
GeoVax&#146;s products, GeoVax will be able to enter into favorable manufacturing and distribution
agreements, as well as other risks and uncertainties, such as those detailed from time to time in
the Company&#146;s Securities and Exchange Commission filings, including &#147;Risk Factors&#148; in the Company&#146;s
most recent Form 10-K. The Company does not undertake to update its forward-looking statements.</I>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax, Inc.</B><BR>
<B>Add 2</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 70%; margin-top: 10pt"><B>Contact</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 70%; margin-top: 10pt">At The Investor Relations Group:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 70%; margin-top: 10pt"><B>Investor Relations</B><BR>
James Carbonara / Jason Strominger
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 70%; margin-top: 10pt">or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 70%; margin-top: 10pt"><B>Public Relations</B><BR>
Janet Vasquez / Robin O&#146;Malley
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 70%; margin-top: 10pt">(212)&nbsp;825-3210
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax, Inc.</B><BR>
<B>Add 3</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
Condensed Consolidated Statements of Operations Information<BR>
(amounts in thousands, except per share data)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Three Months Ended</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Six Months Ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">June 30,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">June 30,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Grant Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,737</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">753</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,076</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,463</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,742</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,203</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,111</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,060</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">936</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">906</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,605</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,630</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,678</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,109</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,716</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,690</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(933</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,349</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,624</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(2,210</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income (loss)&nbsp;per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.06</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.09</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.10</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.15</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
Condensed Balance Sheet Information<BR>
(amounts in thousands)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">June 30,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Dec. 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,808</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,516</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,140</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">365</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,948</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,881</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">285</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">344</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,847</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,315</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">571</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,623</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,744</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,847</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,315</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Shares Outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,655</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,633</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">###
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c04441c0444101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c04441c0444101.gif
M1TE&.#EAP@!$`/?_`!U>F4F*M9R^U%&.NN+L\J;%V&"8OL[>ZFZAPS5XJ?3X
M^5V6O2YQI562NIJ\TH>PRXRTSB9IGGJHQ]3C[.OR];[4XM?D[I"WS]_J\2)F
MG=#@Z\+7Y;3.WD&%L3J`K92XT"=IH!I:E\S>ZDR,M]GF[A=<FC%UIZG&V1A7
MD[W3X>OR]&&9P+C1X-SH[\K<Z=WH\+K2X66;P!=9F<C;Z.CP]"ILHL38YMCF
M[DZ-MX.NR]KG[SA^K.7N\R!BFSZ"L'2EQ='A[(2ORQQ<ET>*M3I_K+?0WRAL
MH*#`U1A8E;+,W=CE[I>[TL;8YH"MR5J5O-+AZT6(LSR"KD2%LF6<P:S(VGBG
MQB-FG6V?PY_`U1]BFQY@FA=?H,G<Z8JRSC!SI1A8EBMMHC=]K%:2O,?:Z&F>
MP<;9YS^"K[;/WAQ?FR)EFRALGT.'LV^BPS)VIR]TIQ9>GAE<F3A\K#AZJ1=A
MHA=8EA=:F!=7E?[^_A9;FA=;FA=6E!=;F1=<G/[___S]_?O\_!=9EA9;G/W^
M_A9<G/W]_??Y^A9:FOG[^^?O\Q=7EO#U]_K[^_/W^.KQ]/W]_N#K\8JRS?CZ
M^N;N\_+V^.[T]M[I\/CZ^\S=ZN_U]L'6Y&N?P_+V]_'U]T"#KQI9E>'K\A9;
MF^'K\?GZ^W.CQ2QOH^_T]G:EQO3W^'>GQZ_*V_K\_'^KR%F4NXBQS2%CG'^K
MRC5[JL#5X[_5Y(VSSK7.WAI:E:/"UIF[TJ[)VRUPH_[^_W&DPZ3#U_K[_!=>
MG7RJR9J^TOO\_96YT>#J\?'V]^SS];#,V^/M\EZ7OG"AQ/;X^IF\T?;Y^;'+
MW+#,W!U@FO;Y^CR`KN_U]WJIR&B<P:K'V2QOI(BRS+/.W5".N!9=G?#U]A=;
MF'RIQQ==FSA\JKG1X#1VIYN]TW6FQ7&BPVB>PJ'"UJ'"U1YBG,/7Y2ALHJ[*
MW#!XJ'>GQ1]AFL_?ZX&LRM;C[OS\_=7C[3E_KBIPHNWT]E>4O,S>Z:'!UE./
MNY*XSXBSSA=6D________R'Y!`$``/\`+`````#"`$0```C_`/\)'$BPH,&#
M"!,J7,BPH<.'#OT)0-*/3@8-_B!JW,BQH\>/($,:U(!'#PH`QT2J7,FRI<N/
M_A;4Z2?CPLN;.',V],>SI\^?/5<6"Z%'3PA..I,JA>COCJ!%"BA)JC3O4BQ:
MU8X(@]0$%8(8"QID&S"DD]FS0P9D:[`@!@)432`).U*-5J9+\RI)HJ1@D:,[
M&0\*D]&O#IG`2Q/G]*?+CX)&+RX5.?+@RH`=I-(`0&*G3AX^@P8%XL,'3XD2
M>5+O62VCCNO7,E;O29WG-![2@4*#RE/'#A(`:=3LR';EP1$6EW18\A,!1<46
MBJ.KU/4'4Z49U:ZMB*(&`(HZ>$;C_\G3FHYY.W90J%>/WKQYUS)2&SI=`H_]
M^_A/&U+=&I![]X"X-MMM@>!A"`_XS$3'#H18\`(F?^@BW80*^4/()I7$XH`F
M1$3@"7BE\78>"GKTTX])=KQ76WB#\)$''2AX\DP:$>0"2P<XL.+6.+\T<0TD
M0`8)9`Z_5,$&-0N0180):ECACA`5R1">-R'*4((4A.!`!TT5*"*##)Y$0(0F
M#L12R2:$($9A4G<4\H@L%S1`BA!UD"9B>B:::%(B=-1A"!\%SN1.#3NP4L4%
M!8!SB06?-*((-(L0<@=@03'5TZ2"_!$)(\7PH,,[F1@#3`[E2,&`!HW8T0\*
M:13R0"!T!/_H&6EU"$%*`Q?(\D@A=ZS)DC^%8$"+!#MD`<AH>]"!9YXGIFAE
M:70(44,'"`B#C0@8%%,((7VHZ>M`/`&6PTQU/'#'+@FD09.==9@'R!Z``I+%
M#MW0@D$AWG[+T!V87'+!$#W4$4@)[3K'[*I]EA!('OV`,$0WU5Q"`"-^Y*LO
M0Y;TH*H=B/S3U"'VD%#!+=3`HO%M(B8<2!T]#''!)=+T>K%!_FS"12NPU(('
M*#+`>/")B8`7""!:1---*A-0\H?%,T/$@8(X,-U4)))<8@X9)@"P1R"&M$N'
M#*#@4<LWK7"Q"=/1^8'!$5((85]O)1Z,`AWPY@$`/?"`\T@D,C?_+=(=L&Q9
MQPP/-74*"<:,PDXM)?#1<Y_V"2&%.1CX,>$?%CQ`2ITRV!'WP7;(X*(K`V!A
M@0)]^\V2#H#T8X<:EG=TAR+O+!'`,Y]Y+7H=I#Q@P1]*.5+)`T;D@8?//^M!
M1WVU2"$."9&@K7I(_I`QDPP"J.0/-//<TH'.)2A+QWA&/%")(S<I4@`L4M+Q
M^<'+&V(%`ALHTL?T"W7+DT?$$&64(BZ973I&887ZB`\/,H!%`;:Q$G\\X@>>
M`$4=#/8S.Q@O#570@"@<\@<,%.$#$AC%#U;1A!*:$`+8(,12"@$)9,1`$RF0
M'D*.0)@ZQ$"&(.G%/(*@AM,DXCN@\,0/_QZ!PPHI00QU*(&J?F:B\>EA!3.(
M1$1XP$.!F88^6*P/'K0QBB**1`4A,$T@+J$1/Y!"58#0P5+^`(1=```/$[0#
MP>ZA!"\6!`-BF`T%?P:>&@"#`G;$!`+&YS,]H.>0Z5D/"NP`@$,D)A,S^4(`
M[/@/$;2.#G)(G5(8T0QZI$8]>=B#&#``$05TPS-[/!AX=@`#1T)D`^C`P\:V
M9@@Z(.$_N/1&"*2X%$%X@2*)X$'A&B`X#E!($!-P`BI1P)MN**`A7`"!$IG8
M1#PD(!TJ9(H`7N2Z$J"@`=68P#$D04YR?F(8Z!S&!J+`#,6D8@\T><5#&O&%
M5;FB$+[R!P96L/\'PJ"@!"#@@D($T05N4E,/><@"+H"G$7\XP)N%H4,.`.D0
M3KARA3U03Q;PV9!9U#`'%_.'$M90@D14)`\0$,1!_K``/*2261:,`5(XDHX\
ME&@/7JC$1B@ID@<09@^I:,@AK.`<CC7-$>L0`CQ1@(<%&(008B@!-9MH!P[P
M=""<>(9)96"&9^*O(!2H)QW:H-*%5(`P=!C!5772B#48PD0E>`=!*+`*J4Z5
M#E908T?\H0EXTB$7RO@JS632#T!,8"%W,(/@"#>]/_S@K?UX1B,$X@\HR.!]
M\+-"QSPB"1BA`!"D%*Q!XG%)9$CO$5MZ7>RFUX=6,`P/4L@(!OBP)6K_HB`$
MH?5($VKXBYOXPP^6.$2:-'('55A"%9J\0QC<%X)B*,04UQ-'0?I0"`HT8A+9
M7`0!$-$(R_F#$QC@`2(040Q-%F01-!@O`7C`4(;TX0J7Y0,IQV'3J<J@`"#Q
M@QH\UUR74*(``S!"#UR1"P-P8!+[:D$K=F"%'E@A"A"HQ/T$PH(:V@0A"@!`
M44(`0(%,H@!2T,*JA)"+:;3`#\MH5QB*X0]15*,SZ$%&-@UR#`8DP@YX\,`G
M)MR013"@'WD8Q3]Z@%EF(<$$,^[()U25UK4FY!"00`(?DN6>SP#@%NVE\0#V
M`$?W@&</#=AL+XAJAP@L`B%4@*<-,W*':CS#_W'*:@]J-#&!'HSO!X&Q0`B4
MA8<<Y.L0UMB#'`-PT8?,X++N^,<2J5F':H0$!C_E!4LH``M95N1/+MH2'4#A
M@TT<!`:)R(-Z0`1'4`(B$P+9!V%D4(&#.,($%`$$"?[QAQ4<[]*`@J-)\O"D
MBC@!,1J`D1[VT&J"^`,!:&4`+S5""#ZX[A]GG"H@"!`2!Q`&$`=`B",NP0%:
M>/O;W^8`#(A!$$6``*T`10`P/K""'DPS#U[@Z$!2D(>MUH$(01!'#L+@FBBE
MXQ^8(`H=HF#>"6@Z`9-J`!Y650)7[((*29@%++BY1#JL0$U'8!@CA3GOI0+B
M$Q[9,RG^L822,/$D,__]2"OJ4)3<$N0.,0B-S&<^<RM00B!WL&QA`8"-BP*K
M`'L&L@$0@PA`J"H/:VA!W^Y@`2+X-004^`<U%.1RCQF@=74P9LE=1X</!'8@
M@KA$/6;2Q(N_G)\5<0,OBX$&5>V!"A]QQR!N`?#5G!SJ(0D"R_7PB(/00%E3
MS1,>\/L/<#",#FK8K$$>X0I5R<`"`NG#"&:RAW*LEB!_<`(W"J,/?0J.#06A
M!%%0T(-%8`(0[+$!0C;1AMI:W%N68,"6]C#T.W3@>F8/>0EFVHT0+)I9=-!`
M2`93V"<<I!(""X3RE[]\LLM@&?_PY99"H-.$7$)P0_\'!C1-A,N?UP2:EH3_
M/Q2K!R$@>"!+6#5(?5H8+"B$`MZI2.X)<@S?]V,/6-B'7XT@;X[<80X/,!!_
M8'@O!0@($!)%`$][@`L'T0+64`"RD`(2.($5(`LKX'C2]0@F!0C=L!#^$``_
MY`X;=`&$D0A*L!#7=W_"\`\;L&KY((!&L#&-<`?[90<,X'T&<0$*,G\$87@E
M8AX(HU<>D0Y1D&0.90@O!0<T`!*50!%T8%H&00.EH!`&1Q/98PS7UG<+@0M[
M4!0\X`^=P!GA8%X%X0<Q2`>3%`PQB`2D$#MEH"#9X`^-<"(RL((+P0,A('\6
MXP_=P#!%<7]'`!+2$`+]1UD%T#,'`PA04%8=L0AI_T`B`,`(!D&&!/$.6X(]
M_S`+O9$&&V1L&M`*K[`*JY`#0^`Y=$`"--@9J,`0,:$L1M`KXE!#9/2!6\(-
MV69P>B`#(L`0?V`%*<*#!.$'^N!Z4\!C'#$)1(!J"'$)&6`([Y,'K^!D'K,+
MY`)]&G$`EY@]>J=:!>$".T,?MZ8\+4`(1%4'$,"*/Z`L$6`YBB!PV?`/B&!2
M2.`%Z!-LR@-Y"R$(^_5Z";$$9$<''>@1/*`)(*<0BH`,AM`Z>9('74")#5$)
MK8,"SW!S$(&-5O@/.DAZ_></*R`#BK0>H78,J4@'!^B!`Z`L8-`K_G`%,X$"
MB.!1]\>`_W`#2*`'=:!Z"_^1,7,#C`.!`6CP.75`"QSA#T]`!6?F7F7``+=V
M(B6@"87&%-DP$X`0`$G&$!:)B156$?A(64ZP,KCD'U4`&".@+-:`@P4Q5'/3
M>0)1":D%!59@$CW`4=+@"399!0RA!)K&D_]@"=8@.#-A!Z"E$:(P`8KG$(=0
M`%9`6R9B"+!0=0]1=,Z1!\G`B%9YB=)%`Z8X?_[0`-U0"9\0"J`9"H_0"($A
M`&B%DPGQ-#1!>/^@"XI5$8X'4C@7.'J0!>>'$/Y@`'F9+WSE5YW0``IB!%_'
MBH6`"0ZY$,Q0`&J`0-]!!_M@"1Q1`':5!_?@595)$]*56%L""!LP$'=0`3*$
MF?W_D`A@<`H)40I$I1[.-1"90!AY`@A+.!#5P#`V1)D%80,*R8\%<08:]PR*
MH`IN,'L-<)S@0J`]%@M#`![@80TI4)6L:`H+!V01``-9AA!/8)D"\0[P9`<A
M4`:!8:"]61CT0)%@!7[WAV>8MU]-Q`IJ(@H@,'O34*$>,P/VIX<%@0@`X#DR
M\&__P`,Y"F07P#1WL#0M<0>?T`K2%!H[D`YFF1!W,`J6MCP,L`0D,`E_X`=8
MFJ5^0`BR@*$>0P9OU1F[@`'R`!0^01",X`J"DP4%8)Q-00E8``#7$P'6.1#`
MX)YU8'P%<0FB!F3TP`2\\EL$\`.]D2?Z*1!_``NMDP<2_X`8L="%N<@$!7$'
MF\`#BB`(TK@0AR`"R>`.;[`%UH`+=8I8X@`([KEI>R`$5E`#K-JJ-4`*KF`B
MF"@0B]`!4O5/=5`#/A`%O-JKO!H-FJ`"`T$"(:`@>.`)"6`&;8`$MU8':%!]
M!<$)`A<.]NDQMF`()N49/?`-/@`&R^,<$V2CE+4*AY<`6>8/#Z!Q```#%$`!
M0,`"*7`,3>H2A2`"59`%6U`'H_`"!BH0.M`)>"!HJY(BN.0>2S2K`B$*R*!K
M<_,:#OL:?$`*,Z8#8'!KG5$'1E<1H,``CDE9"/`N28";S?"MRN,:P@8(AC`$
M`.!K!%$$+/=9'$<0@C`"72@#^?\:!;9``YGJ$<'0`DL`?C6P#SQ@H(XP`SB`
M`J6Q!P^[M$D4`*ES!S#@!B7@#4K+M!#K`@2A`$$0`GQ0`JWQ+`#0"H58$)50
M`F@`G0G!`\A`!RXB(/8!!BS@!T[@(L]@GH)0`-[`&WP05`<Q"2!@"&K0!950
MK1-2,V-@"D0P`DN@`S):$/Y0##`0!/H0#410N99[N94;!^"@27^@`7&"N:`;
M#4[`8@3!"46`"E"P`U"`"C!PFTZZ`.[G@9)0`#%@!L/1"B)PE*?`!O2P`Q(`
M!)#@!6%`!!Z`!6C#""W0N!ZH`'Z@4O,*$G=0"C:P##EP!.]0"NA3(7VPO=S;
MO=Q[!X[_(#7>.[Y],"FXV2V64CC^@+X&L;V9\A?<>Q.5<`D\(`Y]0`9)H0O*
M@`$',`/B5`B8*EH"+!*;0`(8D`\O4))+82&'0`REH`"'4#$#/,$;00,O8`,M
M(`M"22%-L;X[2\&JXP^H$RX@7,(F?,(HG,(JO,(LW,(N_,(P',,RG!"!\<'[
M,\,F+`@?D`J!40:ML`B'``$'P`/\$)]W@`7BT"L"8`N!P0@0P`N!@0D0,&LI
MT`JK\`JV,%D"\0G)P``=X`S]NA$;\`L.BL,@H0*#8`H9X0]>H`>",`];@`TW
M$,<"H0%;X'Y_``"'Y3$QL`7]<)2TL`4NX`\%E`M&,`ATH$8$_U`';2`."[`%
M0>H2,"`,'VS&!#$#?``$B.H)!O`/O)`'/$`)=6`+_W`']``&EC,#8%!6%F`'
M`Q`"6MP-=L`(IV`'IK"]&E`'DR0,AN!<_E`%AR$0A*`$DN@/E4!M"@`#!3`!
M,L,(+-`,F^5`N)`)4G0'.L`(_M`"E/`(2:`#:_P(N&`#1\D,%5``.F",EDP0
M^G<!8S`&Z8=?"Q`"JA`)2'`-_W``@="=_C``#B`0CN`%*[!]V78'"0`&_C`/
M?``#E)4`$?"=VF``)-`+'C,0S)`''_`/QS`(*<`#=+"Z=-`*_T`":&`-;<`'
MLN`/$"`#40``KJ``%,`'F:``=.`*G?^``H80"OX@#'8P!"#P#:J@".J@#^W@
M"]*5SHX[EG20&CUS`W=@!3Y@(?-S!SL`"[VR"4*PGM5`!Z?@!X"`7PJ`!%?P
M#^>0!]3F,2;``#P1I]H0`N*`&$W=!/[`"@C7"+3@!SF7#:)@!=D@"'<0!$>@
M`7S``OY``<@0"H=6#$I0`L)P!TR`!Q9``'B0!(XP6^F0"5O``8*@!-YLU`31
M"UH0`)-P"HS0`$@`#:5@CAY##_H0"WB@IR<06_^@`$*0!N!P`K;\#SJ`!\[P
M#ZP```Q5#(!`#D[Q#\&@`S@P"/$`+@&@"96P!Y!'`P*0#-D`!UA0"7D@?`/Q
M"UEP>0\``(3_P`N`($5GD`B*\`%PX`,=,`3JD`)_P`IU8`6"S=GTAW^4U09>
MX`^7P`>JYP_EX`H@,$FEW`:MY@\_(`-M$`%6$`)1X`^I@`>5T-23),)#X`T\
MD`D1P'$3,`BQ0!"OX`5K,`!R2`<7P`@B4`?SH`1Y$`K$/0/$P`9&D!$4<`E^
M$`4#T`=.``L9D0PUX`@_8`238`FA<``*,`D__0"^D&WR+1"TX`MR]0^*4`?D
M\`\04`+Q"0'>8`BA10!9`)U*,`BS@"FL@`2%,`5(<`@4(`,@<`4-D`A\<`+_
M(`E\P`XP4`0,D`62.!`%,`@R(`G_,`:^4`&4H`^`,`F<(`,QH`,-J@`(C.`,
M?&`,V#@%C$`'`D`(0B!/=Y`&,5!X)9`"E>`#R!`)KH``"G`&@7`#22X05*`/
M7G4,4"!7#[``V70)`4#)'O,+J]@'38`,[04#.(`(/Z#&+3`"(Q`%`;`$Z_D/
M+;`&?&`(4S"%!*$#0W`.`N$'T]`/!A`$3@`\3Q"@#8`)T7<+_8`$25P,(T``
@A3`"AW7NA','0&<'HR!%&!`%G@`+,U#)IW[O#Q$0`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
